#Telitacicept
LightNews LightNews
hswapnil.medsky.social
Big win for telitacicept in SLE (not lupus nephritis, yet)

www.nejm.org/doi/full/10....

BAFF + APRIL FTW

#nephSky #Lupus
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus | NEJM
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (S...
www.nejm.org
October 16, 2025 at 1:04 AM
hswapnil.medsky.social
B-cell modulations keep advancing

Telitacicept and albuminuria in IgAN in the NEJM
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial | NEJM
The pathogenesis of IgA nephropathy is mediated by B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Telitacicept is a fusion protein that targets and neutralizes both BA...
www.nejm.org
May 13, 2026 at 11:28 PM
hswapnil.medsky.social
A #NephJC short of the telitacicept trial from @nephromommy-akshu.bsky.social

www.nephjc.com/news/2026/sh...

IMO the exciting part of the early signal of GFR stabilization - if this is recapitulated with atacicept and sibeprelimab - then we can truly say IgAN remission is here and achievable
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
www.nephjc.com
July 5, 2026 at 5:32 PM
mithurheum.bsky.social
🆕 Visual Abstract w/ Healio Rheumatology 🟢

#Telitacicept in Systemic Lupus
• telitacicept: TACI-Fc fusion protein which targets BLyS/APRIL
• telitacicept: ⇡ response rate vs PBO

📖: van Vollenhoven et al, NEJM
📎: tinyurl.com/telitacicepthealio

#Lupus #MedSky #RheumSky
@gohealio.bsky.social
January 7, 2026 at 7:23 PM
hswapnil.medsky.social
Today’s LBCTs and late breaking science!

Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD

#KidneyWk
LBCT session
November 8, 2025 at 2:11 PM
sodatroubles.bsky.social
Belimumab versus telitacicept in sequential treatment after rituximab for refractory #lupus nephritis: a real-world multicentre study
#nephsky
lupus.bmj.com/content/12/1...
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study
Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to compar...
lupus.bmj.com
January 9, 2025 at 8:17 PM
hswapnil.medsky.social
B-cell modulators in IgAN move into the post transplant recurrent phase!

Telitacicept, in @kireports.bsky.social

www.kireports.org/article/S246...
Figure 1 Changes in proteinuria during follow-up. Longitudinal changes in (a) 24h-UP and (b) UACR in kidney recipients with recurrent IgA nephropathy with add-on telitacicept treatment. 24h-UP, 24-hour urinary protein; UACR, urinary albumin-to-creatinine ratio; ∗P values indicate comparison against baseline: ∗∗P < 0.01; ∗∗∗P < 0.001. Figure 3 Changes in renal function during follow-up. Longitudinal changes in (a) SCr and (b) eGFR in kidney recipients with recurrent IgA nephropathy after add-on telitacicept. eGFR, estimated glomerular filtration rate calculated using the Chronic Kidney Disease Epidemiology Collaboration equation; ns, not significant; SCr, serum creatinine. ∗P values indicate comparison against baseline.
April 20, 2026 at 4:26 PM
markusathome.bsky.social
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.

www.nejm.org/doi/full/10....

The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
October 23, 2025 at 5:47 PM
kireports.bsky.social
Efficacy and Safety of #Telitacicept in #Posttransplant Recurrent #IgA Nephropathy

#VisualAbstract by NephroloverPriti

https://www.kireports.org/article/S2468-0249(26)02759-2/fulltext
April 27, 2026 at 1:01 PM
hswapnil.medsky.social
compare this with the almost flat GFR slope from interim telitacicept data (while we await atacicept aka Trutakna data)

www.nephjc.com/news/2026/sh... from @nephromommy-akshu.bsky.social
July 10, 2026 at 1:13 PM
nejm.org
An interim analysis of a phase 3 trial involving patients with IgA nephropathy showed that 39 weeks of treatment with telitacicept led to a greater reduction in the 24-hour urinary protein-to-creatinine ratio than placebo. Full TELIGAN trial results and Research Summary: https://nej.md/4uFpMLz
This image contains part of the research summary from an article in the New England Journal of Medicine about a phase 3 trial on telitacicept for IgA nephropathy. It includes a diagram showing the how telitacicept works. A graphic below compares telitacicept and placebo groups, each with 159 participants. The patient demographics are 318 adults, with an average age of 38 years, and a gender distribution of 54% women and 46% men. There's a prompt to read the full research summary at NEJM.org.
May 27, 2026 at 7:00 PM
nejm.org
18C010 phase 3 trial: Patients with systemic lupus erythematosus need more effective and safer therapies than those currently available. Research findings on the dual cytokine inhibitor telitacicept are summarized in a new Quick Take video. nej.md/3J0YGg0

#MedSky #Rheumatology
A visual representation of the 18C010 phase 3 trial, which assessed the efficacy and safety of telitacicept in patients with systemic lupus erythematosus.
October 17, 2025 at 1:04 PM
nejm.org
New in the October 16, 2025, issue of NEJM:

Sentinel-Node Biopsy in Cervical Cancer (PHENIX phase 3 trial) nej.md/4oaZled

Telitacicept for Systemic Lupus Erythematosus (18C010 phase 3 trial) nej.md/42EmA7I

#MedSky
Images and descriptions of what's new on NEJM.org this week
October 16, 2025 at 1:07 PM
hswapnil.medsky.social
Cool - which molecule is that? Telitacicept, atacicept, povitacicept…

These do seem to be very promising - Phase 3 dropping at #KidneyWk ,
October 29, 2025 at 1:04 AM
labwaggoner.bsky.social
Efficacy of Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL, in adults with active systemic lupus erythematosus @nejm.org
www.nejm.org/doi/full/10....
October 17, 2025 at 1:37 AM
nephjc.bsky.social
🚨Another #NephJC 🩳 #NephSky
The evidence keeps increasing for new therapies in IgAN🔍
Telitacicept: an APRIL/BAFF inhibitor for decreasing proteinuria in IgAN
Blog by @nephromommy-akshu.bsky.social
www.nephjc.com/news/2026/short/telitacicept7526
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
www.nephjc.com
July 5, 2026 at 4:07 PM
nejm.org
TELIGAN trial: Telitacicept, a recombinant fusion protein that dually targets and neutralizes both BAFF and APRIL, had clinical efficacy in a phase 2 study of IgA nephropathy. Findings of a phase 3 study are summarized in a new Quick Take video. https://nej.md/4d8eqtV
A still from a Quick Take video summarizing the results of the TELIGAN trial. The still shows a kidney with a close-up showing IgA nephropathy, alongside a syringe and vial labeled "Telitacicept."
May 19, 2026 at 1:00 PM
nejm.org
In a trial involving participants with systemic lupus erythematosus, the incidence of a clinical response was higher with telitacicept than with placebo, although infections and reduced immunoglobulin levels were more common. Full 18C010 phase 3 trial results: nej.md/42EmA7I

#MedSky #Rheumatology
A graph showing the response on the modified SRI-4 over time (full analysis population).
October 15, 2025 at 9:40 PM
acr-journals.bsky.social
Prospective cohort study in China evaluated telitacicept + SoC vs belimumab + SoC (historical study data) in childhood-onset SLE. Findings showed telitacicept + SoC improved attainment of LLDAS and complete response

Arthritis & Rheumatology
doi.org/10.1002/art....

#Medsky
Treatment efficacy comparison between Belimumab group and Telitacicept 6 group after and before adjustment using propensity score-based IPTW. A) weighted and unweighted SLEDAI-2K scores, B) weighted and unweighted PGA, C)weighted and unweighted steroid doses. P-values were calculated using rank-sum tests due to the non-normal distribution of the variables
October 31, 2025 at 4:42 PM
nejm.org
An interim analysis of a phase 3 trial involving patients with IgA nephropathy showed that 39 weeks of treatment with telitacicept led to a greater reduction in the 24-hour urinary protein-to-creatinine ratio than placebo. Full TELIGAN trial results: https://nej.md/4uFpMLz
Graph showing the GMR of 24-hour urinary protein-to-creatinine ratio relative to baseline over 39 weeks. Two lines represent different treatments: a grey line for placebo and a blue line for telitacicept. Confidence intervals are shown for both.
May 13, 2026 at 10:00 PM
kidneyboy.bsky.social
Zigakiibart reduced proteinuria and hematuria, no loss of GFR over 100 weeks

Atacicept, telitacicept, povetacicept all target Baff April arm

Atacicept is being studies in the Pioneer study
September 23, 2025 at 7:06 PM
nephjc.bsky.social
Additional studies of endothelin antagonists, complement inhibition (iptacopan, avacopan, ravulizumab, IONIS-FB-LRx), and APRIL/BAFF inhibition (atacicept, telitacicept, povetacicept, sibeprenlimab) are currently underway.
The next IgAN update will have much to discuss!

#NephJC
October 29, 2025 at 1:49 AM
maineanjoureg.bsky.social
Dual BLyS/APRIL blockade with telitacicept improved systemic #lupus activity and reduced proteinuria in patients with moderate (and years after #nephritis onset) renal involvement. doi.org/10.1056/nejm...
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus | NEJM
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (S...
doi.org
November 4, 2025 at 8:03 PM
oriabe114.bsky.social
www.nature.com/articles/s41...

📖”Telitacicept, a dual inhibitor of BAFF and APRIL, has now been shown in a phase III randomized controlled trial to improve systemic lupus erythematosus (SLE) disease activity when added to standard therapy.”

#SLE #lupus #phaseIII
Phase III trial of telitacicept in SLE - Nature Reviews Rheumatology
In a phase III placebo-controlled trial, the addition of telitacicept to standard therapy led to increased clinical response rates for people with systemic lupus erythematosus.
www.nature.com
November 1, 2025 at 1:49 PM
nejm.org
Ensitrelvir for Covid-19 Postexposure Prophylaxis (phase 3 SCORPIO-PEP trial) nej.md/4npQqG7

Telitacicept for IgA Nephropathy (phase 3 TELIGAN trial) nej.md/4uFpMLz

Subscribe to NEJM for the latest medical research: nej.md/subscribe
May 14, 2026 at 1:04 PM